SNGX earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -0.18. Updated 2026-07-23.
Soligenix (SNGX) Research Hub
Soligenix (SNGX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.364 USD (-0.82%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.18, market cap 0.00B. This hub links to the full technical, earnings and options research available for SNGX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.364 USD (-0.82%) |
| 52-week range | 0.3454 USD – 0.45 USD |
| Trend regime | Range |
| 14-day RSI | 34.6 (Bearish) |
| Trailing P/E | -0.18 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for SNGX
Covered Call on SNGX: how it works, illustrative setup around the real 0.364 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SNGX: how it works, illustrative setup around the real 0.364 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SNGX: how it works, illustrative setup around the real 0.364 USD price, max profit/loss, breakeven and when to use it. Educational.
SNGX technical analysis: range, last 0.364 USD, RSI 34.6, 52w range 0.3454 USD–0.45 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SNGX in?
Soligenix (SNGX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SNGX in an uptrend or downtrend?
As of 2026-09-11, SNGX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SNGX's trailing P/E ratio?
SNGX's trailing P/E is -0.18, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does SNGX next report earnings?
SNGX is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.155 USD.